This speaks volumes about the way many investors felt about Myriad's Alzheimer's drug development program.

The drug, Flurizan, failed yesterday. Shares dutifully fell. But today they ramped up to a level before the failure.

This makes sense, because the drug development program was high risk, and was a drag on the company's genetic testing business.

Now, investors can bet on a genomics and diagnostics company without worrying that a risky Alzheimer's drug is about to fail.